Value Added Tax (VAT) disputes regarding the reimbursement of plasma plantation development costs frequently become a critical issue in the plantation industry, as seen in the case of PT Wawasan Kebun Nusantara (WKN). The core problem arises when tax authorities interpret the re-billing of development costs to cooperatives as the provision of Taxable Services subject to VAT under Article 4 of the VAT Law.
The conflict began when the Respondent issued a positive correction to the VAT Base for the March 2017 period amounting to IDR 1,279,724,493.00. The Respondent argued that PT WKN acted as a service provider coordinating plantation development for the cooperative, thus the invoices issued represented consideration for services. Conversely, PT WKN, as the Appellant, emphasized that these costs were purely bridge financing in accordance with the regulatory obligations of the nucleus-plasma scheme. Based on Agriculture Ministerial Regulation No. 98/2013, nucleus companies are required to facilitate the development of community plantations, and the recovery of these costs is based on actual costs without any profit margin.
The Board of Judges, in their legal consideration, referred to Law Number 39 of 2014 concerning Plantations, which mandates partnership patterns. The Judges assessed that the transaction constituted a reimbursement of expenses that should have been borne by the plasma farmers but were initially covered by the nucleus company. Trial facts proved the absence of added value or commercial margins that would indicate a service delivery. Consequently, the Board concluded that the billing was not a VAT object because it did not meet the criteria for the delivery of Taxable Services.
This decision reaffirms that not all incoming cash flows from third parties can be automatically categorized as a VAT Base, especially in transactions that are regulatory mandates such as plasma plantation development. The implication is that taxpayers in the plantation sector have a strong legal position to maintain non-VAT treatment for plasma financing as long as it is supported by evidence of actual costs and clear partnership agreements. This ruling provides legal certainty that the role of a facilitator in the nucleus-plasma scheme is not a form of commercial service delivery.
A Comprehensive Analysis and the Tax Court Decision on This Dispute Are Available Here